Liang Han M.D.
Director

Professor Han Liang is a well-known domestic gastric cancer surgery specialist, and he engaged in gastric cancer surgery and comprehensive treatment for more than 33 years. His professional interest includes peritoneal sustained release chemotherapy and intraperitoneal hyperthermia peritoneal chemotherapy (HIPEC) for locally advanced gastric cancer and they were carried out earlier in China. He has long devoted himself to the clinical study of radical gastrectomy and the regularity of lymph node metastasis in gastric cancer. Another interested field is clinical and experimental study on digestive tract reconstruction after gastrectomy. As a core member of the Expert Group, he participated in the national tour and training of standard surgery for gastric cancer for more than 10 years. Participate in the important clinical research of gastric cancer in China.  Presided over more than 10 national and provincial scientific research projects, published 300 scientific research papers and articles, including more than 100 SCI papers. As editor-in-chief, publish two books about gastric cancer and  as the deputy editor-in-chief, the publish another 2 monographs. As a main translation, publish two translations 2. Served as the editorial board of many academic journals, as the Chairman-designate of the Professional Committee on Gastric Cancer of China Anticancer Association. The level of comprehensive treatment of gastric cancer surgery and gastric surgery in Tianjin Cancer Hospital is the leading level in China.

 

Education & Training

German Language Institute, Beijing Foreign Language University, 1991-1992

Guest Doctor, Department of General Surgery, State Hospital St. Gallen, Switzerland, 1992-1994

Visiting Fellow, MDC Molecular Medical Center, Roberet-roessle Clinic, Charte, Humboldt University of Berlin, Germany, 1999-2000

Visiting Fellow, MD Anderson Cancer Center, Huston, Texas, USA, 2007

MD, Medical Faculty, Tianjin Medical College, Tianjin 1980-1985

Current Positions

Director of Gastrointestinal Oncological Surgery, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China. Chief Doctor, Professor of Tianjin Medical University. 2004.

 

Previous Professional Experiences

Director of Gastric Cancer Surgical Department, Tianjin Medical University Cancer Institute & Hospital, 2004-2016

Deputy Director of Gastrointestinal Oncological Surgery, Tianjin Medical University Cancer Institute and Hospital, Chief Doctor, 2000-2004.

Deputy-Chief Doctor, Department of Abdominal Oncology, Tianjin Medical University Cancer Institute and Hospital, 1995-2000.

Resident, Department of Abdominal Oncology, Tianjin Cancer Hospital, 1985-1995

 

Board Certification

Members of Board, Chinese Anti-Cancer Association, 1997,

Members of Chinese Medical Association, 1990,

Vice-President of Gastric Committee, Chinese Anti-Cancer Association, 2010,

Vice-President of Gastric Cancer Committee, Chinese Medical Association,2013

Vice-President of Surgical Oncologic Committee, Chinese Doctor’s Association,2014

Member of International Gastric Association

 

Recent key publications (2014-present)

Deng JY,Zhang RP, Pan Y, Wang BG, Wu LL, Jiao XG, Bao T, Hao XS, Liang H. Comparison of the staging of regional lymph nodes using the sixth and seventh editions of the TNM classification system for the evaluation of overall survival in gastric cancer patients: findings of a case-control analysis involving a single institute in China. Surgery 2014;156(1):64-74

Deng JY, Zhang RP, Liang H, et al. Methylated CpG site count of dapper homolg 1 (DACT1) promoter prediction the poor survival of gastric cancer. Am J Cancer Res 2014;4(5):518-27

Deng JY, zhang R, Jiang N, Liang H, et al. Superior of the ratio between negative and positive LN for predicting the prognosis for patients with GC. Ann  Surg Oncol 2014;DOI 10.1245/s10434-014-4128-8

Deng JY, Jiang N, Liu Hong G, Liang H. Clinical significance of the methylated cytosine-phosphate- guanine sites of protocadherin-10 promoter for evaluating the prognosis of gastric cancer. J Am Coll Surg 2014 Jun 26. Pii: S1072-7515(14)00502-X

Deng JY, Zhang RP, Pan Y, Ding XW, Cai MZ, Liu Y, Liu HG, Bao T, Jiao XG, Hao XS, Liang H. Tumor size as a recommendable variable for accuracy of the prognostic prediction of gastric cancer: a retrospective analysis of 1521 patients. Ann Surg Oncol 2014;Aug 26, doi:10.1245/s10434-014-4014-x

Deng JY, Liu H, Liang Y, Liang H, et al. Methylation of ras association domin protein 10 promoter negative association with the survival of gastric cancer. Am J Cancer Res2014;4(6):916-23

Jiang N, Deng JY, Liang H, et al. Node-extranodal soft tissue stage based on extranodal metastasis is associated with poor prognosis of patients with gastric cancer. J Surg Res 2014;192(1):90-7

Jiao XG, Deng JY, Wang XN, Liang H. Prognostic value of number of examined lymph nodes in patients with node-negative gastric cancer. J Gastroenterol. 2014 Apr 7;20(13):3640-8. 

Liang Y, Deng JY, Liang H, et al. The opsitive impact of surgeon superiorlization on survival for gastric cancer patients with curative  intent. Gastric Cancer. 2014 Oct 15. [Epub ahead of print]PMID:25315086

Jiang N. Deng J, Liang H, et al. Tumor volume as a prognostic factor was superior to the seventh edition of the pT classification in resectable gastric cancer. Eur J Surg Oncol. 2015;41(3):315-22.